Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 6:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 56 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fluzone-High Dose Quadrivalent Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza

NCT05227001
View directory record Official record
Conditions
Influenza, Human
Interventions
PF-07852352 Influenza saRNA 1, PF-07836391 Influenza saRNA, PF-07836394 Influenza saRNA, PF-07836395 Influenza saRNA, PF-07836396 Influenza saRNA, PF-07867246 Influenza saRNA, Placebo, Quadrivalent influenza vaccine (QIV), PF-07871987 Influenza saRNA, PF-07914705 Influenza saRNA, PF-07915048 Influenza saRNA
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
24
States / cities
Phoenix, Arizona • Walnut Creek, California • Greenacres City, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 17, 2026, 6:04 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults

NCT02831751
View directory record Official record
Conditions
Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Interventions
30 µg/strain of Quadrivalent VLP Vaccine, 60 µg/strain of Quadrivalent VLP Vaccine, FluLaval® Tetra (15 µg/strain), Fluzone® High-Dose (60 µg/strain)
Biological
Lead sponsor
Medicago
Industry
Eligibility
65 Years and older
Enrollment
1,001 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
6
States / cities
Redding, California • Hollywood, Florida • South Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2019 · Synced Oct 17, 2026, 6:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

NCT04551677
View directory record Official record
Conditions
Influenza Immunization, Healthy Volunteers
Interventions
Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 84 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Bardstown, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 17, 2026, 6:04 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Systems Investigation of Vaccine Responses in Aging and Frailty

NCT05291676
View directory record Official record
Conditions
Influenza
Interventions
Fluzone, Fluad
Biological
Lead sponsor
Yale University
Other
Eligibility
21 Years and older
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 17, 2026, 6:04 PM EDT
Recruiting Phase 2 Interventional

High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients

NCT05947071
View directory record Official record
Conditions
Immunization; Infection, Transplantation Infection, Influenza
Interventions
Standard Dose Quadrivalent Inactivated Influenza Vaccine, High Dose Quadrivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 17 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
10
States / cities
Stanford, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 17, 2026, 6:04 PM EDT
Active, not recruiting Phase 2 Interventional

High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients

NCT04613206
View directory record Official record
Conditions
Immunization; Infection, Transplantation Infection, Influenza, Solid Organ Transplant
Interventions
High Dose Quadrivalent Inactivated Influenza Vaccine, Standard Dose Quadrivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 17, 2026, 6:04 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age

NCT03698279
View directory record Official record
Conditions
Influenza
Interventions
High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated), High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated), High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated), Fluarix Quadrivalent Influenza vaccine (Unadjuvanted QIV-SD) (Inactivated), FLUAD Pediatric (adjuvanted TIV) (Surface Antigen, Inactivated)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 17 Years
Enrollment
665 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
13
States / cities
San Diego, California • Miami, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 17, 2026, 6:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Simultaneous RZV and aIIV4 Vaccination

NCT05007041
View directory record Official record
Conditions
Pain, Quality of Life, Injection Site Reaction, Adverse Drug Event
Interventions
FLUAD® Quadrivalent, Fluzone® High-Dose Quadrivalent, SHINGRIX®
Biological
Lead sponsor
Duke University
Other
Eligibility
65 Years and older
Enrollment
267 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 17, 2026, 6:04 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

A Deep Longitudinal Analysis of Next Generation Influenza Vaccines in Older Adults

NCT05518500
View directory record Official record
Conditions
Aging, Influenza Vaccine, Dendritic Cell, Vaccine Response
Interventions
Flu Vaccine (Year 1), Flu Vaccine (Year 2), Flu Vaccine (Year 3), Flu Vaccine (Year 4)
Biological
Lead sponsor
The Jackson Laboratory
Other
Eligibility
65 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 17, 2026, 6:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP

NCT03722589
View directory record Official record
Conditions
Influenza
Interventions
Flublok, Flucelvax, Fluarix, Fluzone, Fluzone High-Dose
Biological
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 65 Years
Enrollment
944 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Portland, Oregon • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Oct 17, 2026, 6:04 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older

NCT04622592
View directory record Official record
Conditions
Influenza
Interventions
Instramuscular vaccine
Biological
Lead sponsor
Medicago
Industry
Eligibility
65 Years and older
Enrollment
209 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
14
States / cities
Huntsville, Alabama • Chandler, Arizona • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 17, 2026, 6:04 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older

NCT02553343
View directory record Official record
Conditions
Influenza
Interventions
High-dose quadrivalent influenza virus vaccine, High-dose influenza virus vaccine, High-dose trivalent inactivated influenza vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
65 Years and older
Enrollment
792 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
9
States / cities
Milford, Connecticut • Coral Gables, Florida • Wichita, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2018 · Synced Oct 17, 2026, 6:04 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine

NCT04969276
View directory record Official record
Conditions
Influenza Immunization, Healthy Volunteers
Interventions
Quadrivalent Inactivated Influenza High Dose, COVID-19 mRNA Vaccine (nucleoside modified)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
65 Years and older
Enrollment
306 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
6
States / cities
Glendale, Arizona • San Diego, California • Vista, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 17, 2026, 6:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults

NCT05755620
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Quadrivalent Inactivated Vaccine, Sodium Chloride, 0.9%, VRC-FLUNPF099-00-VP (H1ssF_3928)
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 17, 2026, 6:04 PM EDT
Completed Phase 2 Interventional Results available

High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients

NCT03179761
View directory record Official record
Conditions
Hematopoietic Cell Transplantation
Interventions
Quadrivalent Inactivated Influenza Vaccine, Laboratory Biomarker Analysis, Trivalent Influenza Vaccine
Biological · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
4
States / cities
Birmingham, Alabama • Chicago, Illinois • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 17, 2026, 6:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults

NCT04896086
View directory record Official record
Conditions
Influenza, Seasonal Influenza
Interventions
VRC-GENADJ0110-AP-NV (Adjuplex), Flucelvax, VRC-FLUMOS0111-00-VP (FluMos-v1)
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 17, 2026, 6:04 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101)

NCT02500680
View directory record Official record
Conditions
Influenza, Human
Interventions
MER4101, Inactivated Influenza Vaccine
Biological
Lead sponsor
Nova Immunotherapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 17, 2026, 6:04 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older

NCT05553301
View directory record Official record
Conditions
Influenza Immunization
Interventions
Quadrivalent Influenza mRNA Vaccine MRT5407, Quadrivalent Recombinant Influenza Vaccine, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza High-Dose Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
23
States / cities
Rolling Hills Estates, California • San Diego, California • DeLand, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 17, 2026, 6:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines

NCT03308825
View directory record Official record
Conditions
Influenza, Flu
Interventions
Fluzone Quadrivalent vaccine, Fluzone High-Dose vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
3
States / cities
Council Bluffs, Iowa • Bardstown, Kentucky • Metairie, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 17, 2026, 6:04 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults

NCT02233816
View directory record Official record
Conditions
Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Interventions
Low dose of quadrivalent VLP vaccine, Medium dose of quadrivalent VLP vaccine, High dose of quadrivalent VLP vaccine, Placebo
Biological
Lead sponsor
Medicago
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Hollywood, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 17, 2026, 6:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults

NCT01946438
View directory record Official record
Conditions
Influenza
Interventions
Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),, Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation),, Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
4
States / cities
Santa Rosa, California • Council Bluffs, Iowa • Metairie, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 17, 2026, 6:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults

NCT02258334
View directory record Official record
Conditions
Influenza
Interventions
Fluzone® Quadrivalent vaccine, 2014-2015 formulation, Fluzone I®ntradermal vaccine, 2014-2015 formulation, Fluzone High Dose vaccine, 2014-2015 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
4
States / cities
Santa Rosa, California • Council Bluffs, Iowa • Metairie, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 17, 2026, 6:04 PM EDT
Completed Phase 2 Interventional Results available

High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant

NCT02860039
View directory record Official record
Conditions
Hematopoietic Cell Transplantation Recipient, Malignant Neoplasm, Influenza
Interventions
Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
3 Years to 17 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
9
States / cities
San Francisco, California • Kansas City, Missouri • Cincinnati, Ohio + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Oct 17, 2026, 6:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

NCT05050318
View directory record Official record
Conditions
Influenza Immunization, Healthy Volunteers
Interventions
Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Bardstown, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 17, 2026, 6:04 PM EDT